13F-HR filed by Opaleye Management Inc.
Opaleye Management Inc. filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 46 holding rows worth $376,066,250.
- Accession
- 0001493152-24-006653
- Filer
- CIK 1595855
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 47 entries on the cover page, a total value of $376,066,250 stated on the cover page (in dollars after the unit check, H1), rows summing to $376,066,249 with VALUE read as dollars as filed, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| HARROW INC | 415858109 | COM | 3,820,000 | $42,784,000 | dollars as filed | |
| TG THERAPEUTICS INC COM | 88322Q108 | Stock | 2,215,000 | $37,832,200 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 4,146,138 | $30,930,189 | dollars as filed | |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 610,000 | $28,041,700 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 6,070,000 | $27,072,200 | dollars as filed | |
| CATALYST PHARMACEUTICALS INC | 14888U101 | COM | 1,257,200 | $21,436,112 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 357,500 | $14,214,200 | dollars as filed | |
| IDEAYA BIOSCIENCES INC COM | 45166A102 | Stock | 311,500 | $11,083,170 | dollars as filed | |
| ETON PHARMACEUTICALS INC | 29772L108 | COMMON STOCK | 2,529,887 | $11,080,905 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 307,500 | $10,940,850 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 263,700 | $10,853,892 | dollars as filed | |
| CODEXIS INC | 192005106 | COM | 3,045,525 | $9,288,851 | dollars as filed | |
| BIOHAVEN LTD | G1110E107 | COM | 200,000 | $8,560,000 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 699,000 | $7,647,060 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 897,000 | $7,292,610 | dollars as filed | |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | COM | 1,960,000 | $6,330,800 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 308,500 | $6,250,210 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 563,500 | $6,125,245 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 90,000 | $5,652,000 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 445,000 | $5,353,350 | dollars as filed | |
| PROTARA THERAPEUTICS INC | 74365U107 | COM STK | 2,692,594 | $5,048,883 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 320,000 | $4,800,000 | dollars as filed | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 250,000 | $4,625,000 | dollars as filed | |
| Applied Therapeutics Inc | 03828A101 | Common Stock | 1,092,500 | $3,659,875 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 877,000 | $3,630,780 | dollars as filed | |
| BIODESIX INC | 09075X108 | COM | 496,500 | $3,610,660 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 2,535,000 | $3,396,900 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871103 | COM | 3,985,340 | $3,144,433 | dollars as filed | |
| INTELLIA THERAPEUTICS INC | 45826J105 | COM | 99,000 | $3,018,510 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 265,388 | $2,964,384 | dollars as filed | |
| GOSSAMER BIO INC | 38341PAA0 | NOTE 5.000% 6/0 | 8,000,000 | $2,915,112 | dollars as filed | principal |
| LARIMAR THERAPEUTICS INC | 517125100 | COM | 623,500 | $2,836,925 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 1,140,000 | $2,815,800 | dollars as filed | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 359,370 | $2,799,492 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 2,982,200 | $2,721,258 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 112,700 | $2,584,211 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 150,000 | $1,837,500 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 211,400 | $1,720,796 | dollars as filed | |
| NYXOAH S A | B6S7WD106 | SHS | 344,800 | $1,599,872 | dollars as filed | |
| MORPHOSYS AG | 617760202 | ADR | 145,000 | $1,435,500 | dollars as filed | |
| PRECIGEN INC | 74017N105 | COM | 1,012,500 | $1,356,750 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367102 | COM | 301,491 | $1,293,396 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 975,000 | $1,101,750 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 130,000 | $877,500 | dollars as filed | |
| ALIGOS THERAPEUTICS INC COM NEW | 01626L105 | Stock | 1,297,000 | $861,208 | dollars as filed | |
| KINIKSA PHARMACEUTICALS LTD | G5269C101 | COM CL A | 37,500 | $640,210 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001493152-24-006653 | this filing | 2024-02-14 | acceptance time not in the bulk data set |